10月13日，京新药业盘中下跌2.04%，截至11:20，报19.24元/股，成交1.56亿元，换手率1.11%，总市值 165.66亿元。 京新药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、仿制药、抗 癌治癌、增持回购、融资融券等。 截至6月30日，京新药业股东户数2.57万，较上期减少0.11%；人均流通股28196股，较上期增加0.11%。 2025年1月-6月，京新药业实现营业收入20.17亿元，同比减少6.20%；归母净利润3.88亿元，同比减少 3.54%。 分红方面，京新药业A股上市后累计派现21.10亿元。近三年，累计派现8.01亿元。 机构持仓方面，截止2025年6月30日，京新药业十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股964.92万股，相比上期减少1539.17万股。创新药（159992）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出452.89万元，特大单买入102.38万元，占比0.65%，卖出474.29万元，占 比3.03%；大单买入2557.59万元，占比16.35%，卖出2638.58万元，占比1 ...

花园生物成立于2000年12月，公司于2014年10月9日在深交所创业板挂牌上市。经过二十多年的发展， 花园生物已经完成了维生素D3全产业链的布局。公司四大类产品精制羊毛脂、羊毛脂胆固醇、维生素 D3、25-羟基维生素D3的产能规模都处于全球领先位置。 2025年上半年，花园生物营业收入约6.35亿元，同比增加5.86%;归母净利润约1.62亿元，同比增加 13.67%。 10月10日，花园生物在互动平台向投资者表示，公司2025年第三季度报告预约披露日为2025年10月18 日，具体业绩情况您可关注公司届时披露的定期报告。花园药业目前主要专注于心血管、神经系统等慢 性疾病领域仿制药的研发、生产和销售，暂未涉及创新药。 ...

10月9日晚间，华北制药股份有限公司（以下简称"华北制药"）发布公告称，其全资子公司华北制药河 北华民药业有限责任公司（以下简称"华民公司"）近日获得国家药品监督管理局核准签发的头孢丙烯 《化学原料药上市申请批准通知书》。这一进展标志着华北制药在抗生素原料药领域的产品线进一步丰 富，但面对激烈的竞争格局，其市场前景与战略布局引发行业深度讨论。 头孢丙烯作为第二代头孢菌素抗生素，因其抗菌作用强、耐药性低、过敏反应较少等优势，被广泛用于 呼吸道感染、皮肤软组织感染等治疗。公告显示，该药物对革兰阳性需氧菌（如金黄色葡萄球菌、肺炎 链球菌等）具有显著抑制作用，临床需求长期稳定。 华北制药披露，头孢丙烯累计研发投入为488.62万元（未经审计）。公告同时明确，后续需通过GMP符 合性检查方可安排生产及上市销售。 根据国家药品监督管理局药品审评中心数据，截至2025年10月9日，国内已有17家原料药企业完成头孢 丙烯的注册评审。 添翼数字经济智库高级研究员吴婉莹对《证券日报》记者表示，这一数据折射出该药品市场竞争的激烈 程度，头孢丙烯虽非创新药，但作为经典抗生素，其市场规模与仿制药企的产能投放密切相关。 华北制药在公告中 ...

华北制药披露，头孢丙烯累计研发投入为488.62万元（未经审计）。公告同时明确，后续需通过GMP符 合性检查方可安排生产及上市销售。 中国企业联合会特约研究员胡麒牧对记者表示，相比部分创新药企动辄数亿元的研发投入，华北制药以 不足500万元完成头孢丙烯仿制药开发，体现了仿制药领域的成本优势。但这也反衬出国内仿制药竞争 的缩影——企业必须通过快速、低成本的仿制策略抢占市场。 华北制药在公告中提到，本次华民公司获得的头孢丙烯《化学原料药上市申请批准通知书》，是对其原 料药产品的进一步补充，丰富了公司产品线，不会对公司当期经营业绩产生重大影响。药品生产、销售 业务易受到医药行业政策、市场环境等因素影响，存在不确定性。 10月9日晚间，华北制药（600812）股份有限公司（以下简称"华北制药"）发布公告称，其全资子公司 华北制药河北华民药业有限责任公司（以下简称"华民公司"）近日获得国家药品监督管理局核准签发的 头孢丙烯《化学原料药上市申请批准通知书》。这一进展标志着华北制药在抗生素原料药领域的产品线 进一步丰富，但面对激烈的竞争格局，其市场前景与战略布局引发行业深度讨论。 头孢丙烯作为第二代头孢菌素抗生素，因其抗菌 ...

Core Viewpoint - Shuyou Shen's stock price has shown significant volatility, with a year-to-date increase of 364.51%, but recent declines in the short term indicate potential market concerns [1][2]. Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Financial Performance - For the first half of 2025, Shuyou Shen reported revenue of 126 million yuan, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.64 million yuan, a decline of 619.70% [2]. - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 circulating shares per person, a decrease of 22.60% [2]. - New institutional shareholders include several funds, with notable holdings such as 15.72 million shares by Xingquan Helun Mixed A and 8.81 million shares by Xingquan Commercial Model Mixed A [3].

Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 15.77% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 29, Huahai Pharmaceutical's stock price was 20.40 yuan per share, with a market capitalization of 30.544 billion yuan [1]. - The stock has seen significant trading activity, with a net inflow of 363,300 yuan from main funds and notable buying and selling volumes over recent days [1]. Shareholder Information - As of September 19, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - Major shareholders include China Europe Medical Health Mixed A, which increased its holdings by 12.234 million shares, and Southern CSI 500 ETF, which also saw an increase in holdings [3].

Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with a significant revenue contribution from injectable nerve growth factor (Sutai) at 59.17% and compound polyethylene glycol electrolyte powder at 33.19% [1][2] Stock Performance - As of September 29, Shuyou Shen's stock price decreased by 2.10% to 33.16 CNY per share, with a total market capitalization of 15.843 billion CNY [1] - The stock has seen a year-to-date increase of 347.50%, but has declined by 8.68% over the last five trading days, 38.43% over the last 20 days, and 24.84% over the last 60 days [1] Financial Performance - For the first half of 2025, Shuyou Shen reported a revenue of 126 million CNY, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.636 million CNY, a decline of 619.70% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares per shareholder, down by 22.60% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Institutional Holdings - Notable new institutional shareholders include Xingquan He Run Mixed A, holding 15.721 million shares, and several other funds, indicating a shift in shareholder composition [3]

Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 24.17%, indicating volatility in market performance [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 19, 2025, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - The top ten circulating shareholders include notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - The stock's trading volume on September 25 was 532 million yuan, with a turnover rate of 1.61% and a total market capitalization of 32.76 billion yuan [1]. - Huahai Pharmaceutical has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 9, where it recorded a net buy of -53.101 million yuan [1]. Business Overview - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1]. - The company's revenue composition includes finished drug sales (61.86%), raw materials and intermediates sales (36.75%), and other services [1]. Industry Classification - Huahai Pharmaceutical is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations, with involvement in AI medicine, generic drugs, innovative drugs, cell therapy, and biomedicine [2].

9月25日，苑东生物盘中下跌2.00%，截至11:21，报59.63元/股，成交9139.11万元，换手率0.86%，总市 值105.27亿元。 截至6月30日，苑东生物股东户数5462.00，较上期减少22.97%；人均流通股32320股，较上期增加 29.82%。2025年1月-6月，苑东生物实现营业收入6.54亿元，同比减少2.25%；归母净利润1.37亿元，同 比减少6.77%。 分红方面，苑东生物A股上市后累计派现3.41亿元。近三年，累计派现2.12亿元。 责任编辑：小浪快报 苑东生物今年以来股价涨100.73%，近5个交易日涨0.74%，近20日跌7.55%，近60日涨40.14%。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售78.75%，原料药销售9.22%，技术服务及转让6.79%，CMO/CDMO4.01%，其 他1.22%。 苑东生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、创新药、 ...

Core Viewpoint - Wanbangde's stock price has shown significant volatility, with a year-to-date increase of 71.38% but a recent decline of 4.09% over the last five trading days [2] Group 1: Stock Performance - As of September 25, Wanbangde's stock price was 11.02 CNY per share, with a market capitalization of 6.741 billion CNY [1] - The stock has experienced a 17.36% increase over the past 20 days and a 57.65% increase over the past 60 days [2] - The company has appeared on the "龙虎榜" (top trading list) five times this year, with the most recent occurrence on August 27 [2] Group 2: Financial Performance - For the first half of 2025, Wanbangde reported revenue of 579 million CNY, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million CNY, down 64.29% year-on-year [2] - The company's main business revenue composition includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] Group 3: Shareholder Information - As of June 30, the number of shareholders for Wanbangde was 39,300, an increase of 42.08% from the previous period, while the average circulating shares per person decreased by 30.25% to 14,085 shares [2] Group 4: Dividend Information - Since its A-share listing, Wanbangde has distributed a total of 613 million CNY in dividends, with 122 million CNY distributed over the past three years [3]